UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Network Properties of Genes Harboring Inherited Disease Mutations

Proceedings of the National Academy of Sciences - PNAS, 2008-03, Vol.105 (11), p.4323-4328

2008

Volltextzugriff (PDF)

An Unbiased Oncology Compound Screen to Identify Novel Combination Strategies

Molecular cancer therapeutics, 2016-06, Vol.15 (6), p.1155-1162

2016

Volltextzugriff (PDF)

Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: In Vitro and In Vivo Preclinical Models

Molecular cancer therapeutics, 2017-05, Vol.16 (5), p.850-860

2017

Volltextzugriff (PDF)

Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy

Molecular cancer therapeutics, 2013-08, Vol.12 (8), p.1442-1452

2013

Volltextzugriff (PDF)

A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors

BMC genomics, 2010-06, Vol.3 (1), p.26-26, Article 26

2010

Volltextzugriff (PDF)

EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL

Molecular cancer therapeutics, 2017-11, Vol.16 (11), p.2586-2597

2017

Volltextzugriff (PDF)

Antibodies Targeting Human or Mouse VSIG4 Repolarize Tumor-Associated Macrophages Providing the Potential of Potent and Specific Clinical Anti-Tumor Response Induced across Multiple Cancer Types

International journal of molecular sciences, 2024-06, Vol.25 (11), p.6160

2024

Volltextzugriff (PDF)

Preclinical Efficacy of VTX-0811: A Humanized First-in-Class PSGL-1 mAb Targeting TAMs to Suppress Tumor Growth

Cancers, 2024-08, Vol.16 (16), p.2778

2024

Volltextzugriff (PDF)

Unique functions of CHK1 and WEE1 underlie synergistic anti-tumor activity upon pharmacologic inhibition

Cancer cell international, 2012-11, Vol.12 (1), p.45-45, Article 45

2012

Volltextzugriff (PDF)

1043 Intratumoral mRNA IL-12 can induce a dose dependent immunostimulatory effect within tumor microenvironment in patients with advanced solid tumors

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A1150-A1150

2023

Volltextzugriff (PDF)

1530 T-cell responses to individualized neoantigen therapy (INT) mRNA-4157 (V940) as monotherapy or in combination with pembrolizumab

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 2), p.A1754-A1754

2023

Volltextzugriff (PDF)

886 Targeting VSIG4, a novel macrophage checkpoint, repolarizes suppressive macrophages which induces an inflammatory response in primary cell in vitro assays and fresh human tumor cultures

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A928-A928

2021

Volltextzugriff (PDF)

862 Targeting PSGL-1, a novel macrophage checkpoint, repolarizes suppressive macrophages, induces an inflammatory tumor microenvironment, and suppresses tumor growth

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A915-A915

2020

Volltextzugriff (PDF)

Dopamine presynaptically and heterogeneously modulates nucleus accumbens medium-spiny neuron GABA synapses in vitro

BMC neuroscience, 2006-06, Vol.7 (1), p.53-53, Article 53

2006

Volltextzugriff (PDF)

Macrophages - Controlling the Bifurcation Between Tumor Existence or Regression

Advanced biology, 2023-10, Vol.7 (10), p.e2300047-e2300047

2023

Volltextzugriff (PDF)

PSGL-1 is a novel macrophage checkpoint in immuno-oncology

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e15090-e15090

2020

Volltextzugriff (PDF)

Abstract P105: Targeting VSIG4, a novel macrophage checkpoint, repolarizes suppressive macrophages which induces an inflammatory response in primary cell in vitro assays and fresh human tumor cultures

Molecular cancer therapeutics, 2021-12, Vol.20 (12_Supplement), p.P105-P105

2021

Volltextzugriff (PDF)

Abstract P107: PSGL-1 blocking antibodies repolarize tumor associated macrophages, reduce suppressive myeloid populations and induce inflammation in the tumor microenvironment, leading to suppression of tumor growth

Molecular cancer therapeutics, 2021-12, Vol.20 (12_Supplement), p.P107-P107

2021

Volltextzugriff (PDF)

Minimal residual disease by circulating tumor DNA as a biomarker of recurrence free survival in resected high-risk melanoma patients treated with mRNA-4157/V940, a personalized cancer vaccine, and pembrolizumab

Journal of clinical oncology, 2023-06, Vol.41 (17_suppl), p.LBA9515-LBA9515

2023

Volltextzugriff (PDF)

Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors

Science translational medicine, 2010-08, Vol.2 (43), p.43ra55

2010

Volltextzugriff (PDF)

Abstract 586: Discovery of a novel TIM3 binding partner and a key role for TIM3 on macrophages: Identification of specific antibodies capable of converting immune-suppressive macrophages to immune-enhancing

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.586-586

2016

Volltextzugriff (PDF)

Abstract 5602: VTX-0811, a first-in-class PSGL-1 blocking monoclonal antibody, repolarizes tumor associated macrophages and induces inflammation in the tumor microenvironment, leading to suppression of tumor growth in pre-clinical studies

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.5602-5602

2022

Volltextzugriff (PDF)

Abstract 5613: Targeting VSIG4, a novel macrophage checkpoint, repolarizes suppressive macrophages which induces an inflammatory response in primary cell in vitro assays and fresh human tumor cultures, and inhibits tumor growth in in vivo murine tumor models

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.5613-5613

2022

Volltextzugriff (PDF)

1 – 25 von 156

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(143)
Mit Volltextzugriff
(141)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(81)
Life Sciences & Biomedicine
(48)
Humans
(40)
Physical Sciences
(23)
Technology
(23)
Female
(17)
Physics
(17)
Materials Science
(16)
Aged
(15)
Chemistry
(14)
Materials Science, Multidisciplinary
(14)
Male
(13)
Science & Technology - Other Topics
(13)
Medicin Och Hälsovetenskap
(12)
Chemistry, Physical
(11)
Cardiovascular System & Cardiology
(10)
Immunology
(10)
Immunotherapy
(10)
Middle Aged
(10)
Oncology
(9)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Network Properties of Genes Harboring Inherited Disease Mutations

An Unbiased Oncology Compound Screen to Identify Novel Combination Strategies

Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: In Vitro and In Vivo Preclinical Models

Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy

A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors

EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL

Antibodies Targeting Human or Mouse VSIG4 Repolarize Tumor-Associated Macrophages Providing the Potential of Potent and Specific Clinical Anti-Tumor Response Induced across Multiple Cancer Types

Preclinical Efficacy of VTX-0811: A Humanized First-in-Class PSGL-1 mAb Targeting TAMs to Suppress Tumor Growth

Unique functions of CHK1 and WEE1 underlie synergistic anti-tumor activity upon pharmacologic inhibition

1043 Intratumoral mRNA IL-12 can induce a dose dependent immunostimulatory effect within tumor microenvironment in patients with advanced solid tumors

1530 T-cell responses to individualized neoantigen therapy (INT) mRNA-4157 (V940) as monotherapy or in combination with pembrolizumab

886 Targeting VSIG4, a novel macrophage checkpoint, repolarizes suppressive macrophages which induces an inflammatory response in primary cell in vitro assays and fresh human tumor cultures

862 Targeting PSGL-1, a novel macrophage checkpoint, repolarizes suppressive macrophages, induces an inflammatory tumor microenvironment, and suppresses tumor growth

Dopamine presynaptically and heterogeneously modulates nucleus accumbens medium-spiny neuron GABA synapses in vitro

Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study

Macrophages - Controlling the Bifurcation Between Tumor Existence or Regression

PSGL-1 is a novel macrophage checkpoint in immuno-oncology

Abstract P105: Targeting VSIG4, a novel macrophage checkpoint, repolarizes suppressive macrophages which induces an inflammatory response in primary cell in vitro assays and fresh human tumor cultures

Abstract P107: PSGL-1 blocking antibodies repolarize tumor associated macrophages, reduce suppressive myeloid populations and induce inflammation in the tumor microenvironment, leading to suppression of tumor growth

Minimal residual disease by circulating tumor DNA as a biomarker of recurrence free survival in resected high-risk melanoma patients treated with mRNA-4157/V940, a personalized cancer vaccine, and pembrolizumab

Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors

T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study

Abstract 586: Discovery of a novel TIM3 binding partner and a key role for TIM3 on macrophages: Identification of specific antibodies capable of converting immune-suppressive macrophages to immune-enhancing

Abstract 5602: VTX-0811, a first-in-class PSGL-1 blocking monoclonal antibody, repolarizes tumor associated macrophages and induces inflammation in the tumor microenvironment, leading to suppression of tumor growth in pre-clinical studies

Abstract 5613: Targeting VSIG4, a novel macrophage checkpoint, repolarizes suppressive macrophages which induces an inflammatory response in primary cell in vitro assays and fresh human tumor cultures, and inhibits tumor growth in in vivo murine tumor models

Suchergebnisse filtern